News
Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...
The medicinal cannabis purveyor Bioxyne was the top performing ASX biotech in 2024-25, recording a 720% share gain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback